Smart home monitoring could help pancreatic cancer patients avoid hospital stays

NCT ID NCT04263948

Completed Symptom relief Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested a home monitoring system for people with advanced pancreatic cancer receiving a strong chemotherapy called mFOLFIRINOX. The system tracked symptoms, activity, sleep, and weight using connected devices and an online platform. The goal was to see if early alerts could help doctors respond quickly to side effects and reduce emergency hospital visits. The study involved 58 patients in France over 7 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PiCaDo telemonitoring system (device and internet platform)
What this could lead to: If successful, this could help doctors detect problems earlier in pancreatic cancer patients on chemotherapy, potentially reducing emergency hospital visits and improving quality of life.
What could go wrong: This is a small, completed study with only 58 participants, so results may not apply to all patients. The monitoring system itself does not treat the cancer, and technical issues or patient non-use could limit its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Motor Activity Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREAS CANCER

Contacts and locations

Locations

Clinique du Mousseau

Évry, IDF, 91000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.